Lin Fengning, Lian Junyu, Wu Lijing
Department of Obstetrics and Gynecology, Fujian Provincial Maternity and Children's Hospital, Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian 350000, P.R. China.
Exp Ther Med. 2025 Apr 9;29(6):116. doi: 10.3892/etm.2025.12866. eCollection 2025 Jun.
While Chinese herbal medicines have been used to treat premature ovarian insufficiency (POI), their efficacy is currently unclear. The present study aimed to review and evaluate the efficacy of the Kuntai capsule combined with hormone replacement therapy (HRT) in treating POI. The China National Knowledge Infrastructure, WanFang, Chinese Biomedical Literature, PubMed, Embase and Cochrane Library databases were searched from the inception of the database to 25th October 2020, for studies comparing the therapeutic effect of Kuntai capsule combined with HRT vs. HRT alone in women with POI. The Cochrane Risk of Bias assessment tool was used to assess the quality of the studies, and the results were reported as weighted mean differences (MD) with 95% confidence intervals (CI). The present study included 10 trials involving 742 women with POI. When compared with HRT alone, HRT combined with Kuntai capsule significantly increased the number of antral follicles (AFC) (MD=0.88; 95% CI, 0.48-1.29; P<0.00001), anti-Müllerian hormone (AMH) levels (MD=0.24, 95% CI, 0.13 to 0.35, P<0.00001) and significantly improved peri-menopausal symptoms [MD=-2.26; 95% CI, -3.77-(-0.75); P=0.003]. The combined treatment regimen significantly decreased the levels of follicle-stimulating hormone [MD=-5.60; 95% CI, -7.98-(-3.22); P<0.00001] and luteinizing hormone [MD=-2.42; 95% CI, -3.40-(-1.44), P<0.00001] and significantly increased the level of estradiol (MD=13.94; 95% CI, 4.16-23.71; P<0.00001). Therefore, the Kuntai capsule combined with HRT could potentially be used as a supplementary therapy to alleviate menstrual disorders and peri-menopausal symptoms and improve serum sex hormone levels in women with POI. The observed increase in the number of AFC in patients with POI treated with the combined therapy was indicative of improved ovarian reserve function. Therefore, combining the Kuntai capsule and HRT had am improved curative effect for POI treatment compared with HRT alone. However, as the present study was limited by the quality of the included reports, additional high-quality studies with extensive sample sizes are required to verify the findings.
虽然中药已被用于治疗卵巢早衰（POI），但其疗效目前尚不清楚。本研究旨在回顾和评估坤泰胶囊联合激素替代疗法（HRT）治疗POI的疗效。检索了中国知网、万方、中国生物医学文献数据库、PubMed、Embase和Cochrane图书馆数据库，检索时间从建库至2020年10月25日，以查找比较坤泰胶囊联合HRT与单纯HRT治疗POI女性疗效的研究。采用Cochrane偏倚风险评估工具评估研究质量，结果以加权平均差（MD）和95%置信区间（CI）报告。本研究纳入了10项试验，涉及742例POI女性。与单纯HRT相比，HRT联合坤泰胶囊显著增加了窦卵泡数量（AFC）（MD = 0.88；95%CI，0.48 - 1.29；P < 0.00001）、抗苗勒管激素（AMH）水平（MD = 0.24，95%CI，0.13至0.35，P < 0.00001），并显著改善了围绝经期症状[MD = -2.26；95%CI，-3.77 - （-0.75）；P = 0.003]。联合治疗方案显著降低了促卵泡生成素水平[MD = -5.60；95%CI，-7.98 - （-3.22）；P < 0.00001]和促黄体生成素水平[MD = -2.42；95%CI，-3.40 - （-1.44），P < 0.00001]，并显著提高了雌二醇水平（MD = 13.94；95%CI，4.16 - 23.71；P < 0.00001）。因此，坤泰胶囊联合HRT可能作为一种辅助治疗方法，用于缓解POI女性的月经紊乱和围绝经期症状，并改善血清性激素水平。联合治疗的POI患者中观察到的AFC数量增加表明卵巢储备功能得到改善。因此，与单纯HRT相比，坤泰胶囊联合HRT治疗POI的疗效更佳。然而，由于本研究受纳入报告质量的限制，需要更多样本量大的高质量研究来验证这些结果。
Zotero 插件